Blood fat carrier not linked to Alzheimer deaths in US adults
Alzheimer deaths occurred in 0.72% of adults with elevated levels and 0.83% with lower levels over a median 25.8 years.
Our read
Populations- Studied:
- Cohort study of US adults with measured lipoprotein(a) levels, median 25.8 years
- What changed:
- Elevated lipoprotein(a) was not linked to Alzheimer deaths: 0.72% against 0.83% with lower levels
- The catch:
- Deaths listing Alzheimer disease only as a contributing cause did not count
- In the record:
- The 324th paper on lipoprotein with results in people; 722 on record in all.
Editor of record: Boris Djordjevic · AgingResearch.News
US adults with measured levels of lipoprotein(a), a fat-carrying particle in blood, were included in a retrospective observational cohort study. Researchers compared 1,603 adults with elevated levels against 6,714 with lower levels. They used measurements collected in 1988–1994 and death records through December 31, 2019. Elevated levels meant at least 50 milligrams per deciliter.
Elevated lipoprotein(a) was not associated with Alzheimer disease mortality, either before or after accounting for age, sex, and race or ethnicity. The adjusted estimate’s range of likely values included both lower and higher mortality. An analysis restricted to adults aged 60 or older also found no association.
Why it matters
The authors suggested that lipoprotein(a)-related blood-vessel processes may matter more for events affecting the brain’s blood supply than for the degeneration of nerve cells.
Caveats
The outcome was Alzheimer disease recorded as the underlying cause of death, not whether people developed the disease. The findings were reported in a conference abstract.
The paper
Mayo Clinic; Houston Methodist
AHA Scientific Sessions 2026 Abstract, Nov 2, 2026
Presented at AHA Scientific Sessions 2026, abstract 8894
Comments
Be the first to comment.